Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) is anticipated to announce its Q2 2025 earnings results on Monday, August 11th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.
Aerovate Therapeutics Stock Performance
Aerovate Therapeutics stock traded down $0.30 during midday trading on Monday, reaching $6.89. 143,073 shares of the company's stock were exchanged, compared to its average volume of 12,438. Aerovate Therapeutics has a 52 week low of $56.35 and a 52 week high of $105.00. The firm has a market cap of $199.71 million, a price-to-earnings ratio of -2.30 and a beta of 0.95. The stock's 50-day simple moving average is $8.61 and its 200 day simple moving average is $50.05.
Institutional Investors Weigh In On Aerovate Therapeutics
A number of institutional investors have recently made changes to their positions in AVTE. Jane Street Group LLC bought a new stake in shares of Aerovate Therapeutics during the first quarter worth approximately $28,000. AQR Capital Management LLC boosted its stake in shares of Aerovate Therapeutics by 14.7% in the first quarter. AQR Capital Management LLC now owns 21,633 shares of the company's stock valued at $54,000 after buying an additional 2,779 shares during the period. Rhumbline Advisers boosted its stake in shares of Aerovate Therapeutics by 67.3% in the first quarter. Rhumbline Advisers now owns 22,750 shares of the company's stock valued at $57,000 after buying an additional 9,154 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Aerovate Therapeutics by 12.2% in the first quarter. Goldman Sachs Group Inc. now owns 352,669 shares of the company's stock valued at $885,000 after buying an additional 38,300 shares during the period.
About Aerovate Therapeutics
(
Get Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aerovate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.
While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
